Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

about

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells

P2860

Q34491507-7BBAA691-084A-4572-A95F-DE26BEEF279D Q58122667-1BEF20E2-2282-4187-96C6-39ED3F907B6E

P2860

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

Item

http://www.wikidata.org/entity/Q38575758

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

@en

type

Item

label

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

@en

prefLabel

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

@en

P1476

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

@en

P2093

Ali A Bukhari

http://www.w3.org/2001/XMLSchema#string

Ranjit K Goudar

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.

Cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.

Discordant protein and mRNA expression in lung adenocarcinomas.

P304

436409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/436409

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275460435

http://www.w3.org/2001/XMLSchema#string

P698

26316940

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4437388

http://www.w3.org/2001/XMLSchema#string

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

about

P2860

P2860

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932